Have you been diagnosed with Blood Cancer. If so, you may be able to take part in a research study looking at the safety of giving a new drug called AK117 to patients with Leukemia

In this study, we want to see if AI chatbots give quality health advice to cancer survivors. We want to see if these responses can help providers and doctors respond well to patients' questions and needs.

Have you been diagnosed with s Cutaneous (skin) Lymphoma? If so this could be a good study for you to paticipate in. One of the primary goals of the USCLC is to establish a registry of patients with cutaneous lymphoma in the United States. Such a registry would collect information such as the specific cutaneous lymphoma diagnosis, stage of disease, treatments used, and response to treatments. This information will collected on an online Institutional Review Board (IRB)-approved database/registry of patients from all sites. We hope that this will allow providers to better understand this rare disease by looking at data from many patients. We hope ultimately will include all the patients with cutaneous lymphoma across the United States

Have you been histologically or cytologically confirmed to have Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma that is considered incurable by local therapies? If so, you may be able to participate in a research study seeking to find out if Amivantamab Monotherapy and/or Amivantamab in Addition to Standard of Care Therapeutic Agents can be an effective traetment.

Have you been diagnosed with Chronic Myeloid Leukemia, have a T315I mutation, and previously treated with at least two tyrosine kinase inhibitors (TKIs)? You might be able to participate in this study.

This research study is being done in participants with advanced B-cell malignancies such as some types of lymphomas or leukemias. B-cell malignancies express a protein called the Bruton's tyrosine kinase (BTK), which has been shown to help the tumor cells grow and survive. The investigational drug, AC676, has been designed to recognize the BTK protein, and marks it for destruction. By destroying the BTK protein, the malignancy may be stopped from growing. "Investigational" means the study drug being tested is not approved by the FDA. This is an open-label study, meaning all patients who are eligible to participate will receive study drug. The key purposes of this study are to: ● Test the study drug at different dose levels (dose-escalation) and to determine the highest dose that can be taken without side effects that can't be tolerated (referred to as maximum tolerated dose or MTD). ● Determine what dose of

The purpose of this research study is to compare the effectiveness of two combinations of anticancer study drugs in treating your Chronic Lymphocytic Leukemia (CLL). The first combination is sonrotoclax (also known as BGB-11417) and zanubrutinib, while the second combination is venetoclax and obinutuzumab. The aim is to determine which combination of study drugs is more effective in controlling your specific type of cancer,

Are you a male that has been diagnosed with hormone receptor positive and HER2 negative breast cancer? If so, you may be eligible to a clinical trial comparing different endocrine therapies to treat breast cancer prior to surgery.

Have you been diagnosed with metastatic breast cancer? If so, you may be able to take part in a research study looking at the efficacy of giving a drug called enzalutamide, alone or combined with mifepristone vs standard chemotherapy.

Have you been diagnosed with metastatic breast cancer? If so, you may be able to take part in a research study looking at the safety and efficacy of giving a new drug called DB-1303 vs standard chemotherapy to patients with metastatic breast cancer.